Detalhe da pesquisa
1.
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
Ann Oncol
; 34(4): 420-430, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681299
2.
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Ann Oncol
; 34(9): 796-805, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414216
3.
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Cancer Immunol Immunother
; 72(11): 3475-3489, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37606856
4.
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma.
Ann Oncol
; 33(1): 99-106, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687894
5.
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Ann Oncol
; 33(9): 968-980, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35716907
6.
Novel adjuvant options for cutaneous melanoma.
Ann Oncol
; 32(7): 854-865, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33771664
7.
Immunotherapy use outside clinical trial populations: never say never?
Ann Oncol
; 32(7): 866-880, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33771665
8.
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Ann Oncol
; 32(7): 917-925, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798657
9.
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
Ann Oncol
; 32(6): 766-777, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744385
10.
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Ann Oncol
; 31(6): 724-744, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32194150
11.
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ.
Ann Oncol
; 31(8): 1075-1082, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387454
12.
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma.
Ann Oncol
; 31(11): 1569-1579, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32739408
13.
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.
Clin Exp Immunol
; 202(3): 335-352, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32734627
14.
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Ann Oncol
; 30(5): 815-822, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30860590
15.
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Ann Oncol
; 30(7): 1154-1161, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923820
16.
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Ann Oncol
; 29(10): 2115-2120, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30137228
17.
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
Ann Oncol
; 29(1): 250-255, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045547
18.
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Ann Oncol
; 29(8): 1861-1868, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945191
19.
PET imaging for cancer immunotherapy: the Immuno-PET.
Ann Oncol
; 33(1): 13-14, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34808339
20.
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
Ann Oncol
; 28(5): 1130-1136, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327969